Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03999125Phase 4Unknown

Anti-VEGF Therapy Versus Dexamethasone Implant for DME

Role: lead

NCT01435876Not ApplicableCompleted

Surgery and Convergence Insufficiency Intermittent Exotropia

Role: lead

NCT01425112Not ApplicableCompleted

Comparison of Subconjuctival Versus Topical Bevacizumab as Adjunct Therapy to Trabeculectomy

Role: lead

NCT01424735Not ApplicableCompleted

TLR-9 Antagonism in Steroid Resistant Optic Neuritis

Role: lead

All 4 trials loaded